Sector Gamma AS Has $55.63 Million Stake in Eli Lilly and Company (LLY)
Sector Gamma AS cut its stake in Eli Lilly and Company (NYSE:LLY) by 0.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 661,350 shares of the company’s stock after selling 5,700 shares during the period. Eli Lilly and accounts for approximately 9.1% of Sector Gamma AS’s portfolio, making the stock its 2nd largest position. Sector Gamma AS’s holdings in Eli Lilly and were worth $55,626,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. First Command Financial Services Inc. increased its position in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co bought a new position in Eli Lilly and during the first quarter valued at approximately $135,000. Penserra Capital Management LLC increased its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Crestwood Advisors Group LLC bought a new position in Eli Lilly and during the first quarter valued at approximately $179,000. Finally, Sandy Spring Bank increased its position in Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after buying an additional 750 shares in the last quarter. 75.61% of the stock is currently owned by institutional investors.
Eli Lilly and Company (LLY) traded up 0.26% during mid-day trading on Wednesday, reaching $82.18. 204,978 shares of the company were exchanged. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The firm has a market capitalization of $86.70 billion, a P/E ratio of 35.56 and a beta of 0.34. The stock has a 50-day moving average of $83.03 and a 200 day moving average of $81.54.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.86 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.
ILLEGAL ACTIVITY NOTICE: “Sector Gamma AS Has $55.63 Million Stake in Eli Lilly and Company (LLY)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/sector-gamma-as-has-55-63-million-stake-in-eli-lilly-and-company-lly.html.
Several research firms recently commented on LLY. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. BMO Capital Markets reiterated a “sell” rating and set a $73.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. Leerink Swann cut shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $93.00 to $90.00 in a report on Wednesday, July 26th. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Finally, UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average price target of $88.27.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock valued at $55,845,287 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.